Medicure Inc.

Equities

MPH

CA58469E4085

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 16:32:40 21/06/2024 BST			5-day change	1st Jan Change
1.02 ^CAD	-6.42%		-4.67%	-27.14%

05-29	Transcript : Medicure Inc., Q1 2024 Earnings Call, May 29, 2024
05-28	Medicure Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Medicure Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 28, 2024 at 10:02 pm

Medicure Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CAD 5.69 million compared to CAD 5.63 million a year ago. Net income was CAD 0.051 million compared to CAD 0.29 million a year ago.

Latest news about Medicure Inc.

Transcript : Medicure Inc., Q1 2024 Earnings Call, May 29, 2024	05-29
Medicure Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-28	CI
Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as Director	05-28	CI
Transcript : Medicure Inc., 2023 Earnings Call, Apr 09, 2024	04-09
Medicure Swung to a Loss in 2023 on Lower Sales	04-08	MT
Medicure Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
Marley Drug Announces A Partnership with TheracosBio to Distribute A Newly Approved Diabetes Drug, BRENZAVVY	12-06	CI
Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease	11-23	CI
Transcript : Medicure Inc., Q3 2023 Earnings Call, Nov 22, 2023	11-22
Medicure Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-21	CI
Transcript : Medicure Inc., Q2 2023 Earnings Call, Jul 31, 2023	31/07/23
Medicure Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/07/23	CI
Medicure's Q1 Profit, Revenue Falls; Up Nearly 13%	29/05/23	MT
Transcript : Medicure Inc., Q1 2023 Earnings Call, May 29, 2023	29/05/23
Medicure's Q1 Profit, Revenue Falls	29/05/23	MT
Medicure Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/05/23	CI
Transcript : Medicure Inc., Q4 2022 Earnings Call, Apr 10, 2023	10/04/23
Medicure Brief: Net income for Year ended December 31, 2022 was $1.4 million or $0.13 per share compared to a net loss of $727,000 or $0.07 per share for the year ended December 31, 2021	06/04/23	MT
Medicure Brief: Recorded total net revenue of $6.3 million during the quarter ended December 31, 2022 compared to $6.8 million for the quarter ended December 31, 2021	06/04/23	MT
Medicure Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	06/04/23	CI
Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors	01/02/23	CI
Transcript : Medicure Inc., Q3 2022 Earnings Call, Nov 25, 2022	25/11/22
Medicure Reports Q3 2022 Net Income of $1.1 Million, Total Net Revenue of $5.3 Million	25/11/22	MT
Medicure Brief: Net Income for the three months ended September 30, 2022 was $1.1 million or $0.11 per share; Recorded total net revenue of $5.3 million	24/11/22	MT
Medicure Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/11/22	CI

Chart Medicure Inc.

Duration

Period

More charts

Company Profile

Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Companyâs United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Sector

Biotechnology & Medical Research

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDICURE INC.	-27.14%	7.8M
VERTEX PHARMACEUTICALS INCORPORATED	+16.45%	123B
REGENERON PHARMACEUTICALS, INC.	+21.96%	115B
ARGENX SE	+23.73%	25.85B
BIONTECH SE	-20.05%	20.9B
BEIGENE, LTD.	-16.28%	16.77B
GENMAB A/S	-16.52%	16.52B
WUXI APPTEC CO., LTD.	-44.35%	15.56B
SAREPTA THERAPEUTICS, INC.	+63.91%	15.49B
NEUROCRINE BIOSCIENCES, INC.	+2.52%	13.45B

Bio Therapeutic Drugs